TIAA CREF Investment Management’s NovoCure NVCR Stock Holding History

TIAA CREF Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$14.8M	Sell	308,007 -23,264	-7%	-$1.12M	0.01%	844
2018 Q4	$11.1M	Sell	331,271 -5,830	-2%	-$213K	0.01%	904
2018 Q3	$17.7M	Sell	337,101 -44,476	-12%	-$1.77M	0.01%	792
2018 Q2	$11.9M	Buy	381,577 +61,964	+19%	+$1.72M	0.01%	1039
2018 Q1	$6.97M	Buy	319,613 +181,477	+131%	+$3.9M	﹤0.01%	1348
2017 Q4	$2.79M	Sell	138,136 -13,966	-9%	-$269K	﹤0.01%	1953
2017 Q3	$3.02M	Sell	152,102 -3,231	-2%	-$63.5K	﹤0.01%	1925
2017 Q2	$2.69M	Buy	155,333 +16,760	+12%	+$216K	﹤0.01%	1996
2017 Q1	$1.12M	Sell	138,573 -5,305	-4%	-$38.3K	﹤0.01%	2454
2016 Q4	$1.13M	Sell	143,878 -10,074	-7%	-$81K	﹤0.01%	2463
2016 Q3	$1.31K	Buy	153,952 +825	+0.5%	+$7.52K	﹤0.01%	2397
2016 Q2	$1.79M	Buy	153,127 +124,136	+428%	+$1.55M	﹤0.01%	2192
2016 Q1	$420K	Hold	28,991	–	–	﹤0.01%	2835
2015 Q4	$648K	Buy	+28,991	New	+$692K	﹤0.01%	2803

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

TIAA CREF Investment Management's NVCR Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its NovoCure (NVCR) stake by 7% in Q1 2019, selling an estimated $1.12M and leaving 308,007 shares worth $14.8M. The position accounts for 0.01% of the portfolio, ranked #844.

TIAA CREF Investment Management first reported a position in NVCR in Q4 2015 and has held it in 14 quarters since. The position peaked at $17.7M in Q3 2018. 200 funds tracked by Wall St. Rank hold NVCR as of Q1 2019.

TIAA CREF Investment Management held 308,007 shares of NovoCure worth $14.8M as of Q1 2019.
TIAA CREF Investment Management sold 23,264 NovoCure shares in Q1 2019, an estimated $1.12M.
NovoCure made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #844 holding.
TIAA CREF Investment Management first reported a position in NovoCure in Q4 2015 and has held it in 14 quarters since.
TIAA CREF Investment Management's NovoCure position peaked at $17.7M in Q3 2018.
200 funds tracked by Wall St. Rank held NovoCure as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.